Developer docs
API playgroundTry for free, no card

Search company profiles

Zentiva

Full company profile

uuid0032653

Namestring
Zentiva
Legal namestring
Zentiva Group, a.s.
Websiteurl
zentiva.sk
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Zentiva is a European pharmaceutical company that develops, manufactures, and distributes high-quality, affordable generic and branded generic medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars. Its portfolio spans 1,826+ product items covering cardiology, oncology, respiratory, central nervous system, and diabetes therapeutic areas, serving more than 100 million people across 40+ countries in Europe and beyond. The company operates four owned manufacturing plants in Czech Republic, Romania (two sites), and India, producing 718 million Standard Manufacturing Units annually, supplemented by a network of external manufacturing partners. Its R&D footprint comprises two centers with 250+ experts registered 509 new product filings in 2025, supported by an Open Innovation Program and the PARC academic partnership through Prague Scientific.

Zentiva generates revenue across four primary streams: prescription generic and branded generic medicines sold through 31 active branches and 6 representations by 1,800+ medical representatives; OTC and consumer healthcare products distributed through pharmacies and retail; the Zent2U B2B platform offering API supply, CDMO services, and know-how licensing; and Prague Scientific pharmacovigilance and regulatory services. The company positions itself as a cost-effective alternative to originator brands, supporting healthcare system sustainability across European markets. Pricing is regulated by national healthcare authorities, with quote-based and contract-based terms for institutional customers and public procurement organizations.

Founded in 1993 after the Velvet Revolution, with pharmaceutical roots tracing to 1488 in Prague, Zentiva was publicly listed (2004), merged with Sanofi (2008), spun off to Advent International (2018), and most recently acquired by GTCR in April 2026. Under current ownership, the company employs 5,400+ professionals across 30+ countries and has expanded aggressively through acquisitions (Creo Pharmaceuticals, Solacium, Alvogen CEE, Helvepharm, Ankleshwar plant, Aboca OTC brands) and licensing partnerships (mAbxience biosimilars, Adalvo, Lupin). Recent strategic moves include the Lupin biosimilar deal and Aboca OTC acquisition in 2025, with a stated goal to reach 1 in 5 people in Europe by 2028.

Short descriptiontext

Zentiva is a European pharmaceutical company developing, manufacturing, and supplying generic, branded generic, OTC, and biosimilar medicines, serving 100+ million patients across 40+ countries through 31 branches and 1,800+ medical representatives.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBratislava
HQ citystring
Bratislava
Markets served

Serves global market

Offices31 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, branded generic medicines, OTC consumer healthcare, API manufacturing services, biosimilar medicines
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Generic and Branded Generic Medicines (Rx)
TypeOne Time License
Description

Prescription generic and branded generic medicines covering therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. Products include original brands protected by patents or data exclusivity, and branded generics serving as equivalent alternatives to originator products. Revenue generated through direct sales to healthcare providers, pharmacies, and public procurement across Europe.

zentiva.sk
2OTC and Consumer Healthcare Products
TypeOne Time License
Description

Over-the-counter products and nutritional supplements sold through pharmacies and retail channels, including natural-based OTC products acquired from Aboca in 2025. Revenue from consumer-facing OTC sales across European markets.

zentiva.sk
3B2B Platform Services (Zent2U)
TypeLicensing Royalties
Description

Specialized B2B platform offering API (active pharmaceutical ingredient) supply, CDMO (contract development and manufacturing) services, and licensing of know-how to partners, with deep expertise in cardiology, urology, oncology, neurology, and hormonal therapies.

zentiva.sk
4Scientific and Regulatory Services (Prague Scientific)
TypeProfessional Services
Description

High-quality pharmacovigilance and regulatory services for prescription drugs (Rx), OTC, and non-drug products through Prague Scientific, supporting every phase of the drug lifecycle from concept to product compliance maintenance.

zentiva.sk
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription generic and branded medicines — regulated pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Pricing for prescription medicines is regulated by national healthcare authorities across European markets. Generic medicines are positioned as cost-effective alternatives to originator brands, contributing to healthcare system sustainability.

zentiva.sk
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Zent2U
Description

Specialized B2B platform offering API, CDMO services, and licensing of know-how to partners in key therapeutic areas including cardiology, urology, oncology, neurology, and hormonal treatments

zentiva.sk
+1 more record
Core offering1 text field

Zentiva develops, manufactures, and supplies high-quality, affordable generic and branded generic prescription medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars across therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. The company maintains a portfolio of 1,826+ product items, produced at four owned manufacturing plants in the Czech Republic, Romania, and India, and distributed across 40+ countries to over 100 million people via 31 commercial branches and 1,800+ medical representatives. It also operates the Zent2U B2B platform for API supply, CDMO services, and licensing, and Prague Scientific for pharmacovigilance and regulatory services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100+ million people served across 40+ countries in Europe and beyond
+4 more records
Product overview1 text field

Zentiva is a European pharmaceutical company developing, manufacturing, and supplying high-quality, affordable medicines. Its portfolio consists of prescription (Rx) medicines and over-the-counter (OTC) consumer healthcare products across therapeutic areas including cardiology, oncology, respiratory care, CNS, and diabetes. The offering is structured around branded generic medicines and specialized products, supported by two core B2B service platforms: Zent2U (providing API supply, CDMO services, and outlicensing) and Prague Scientific (providing R&D, manufacturing, pharmacovigilance, and regulatory affairs services). The company also operates an Open Innovation Program and research partnerships including PARC. In 2024, more than 140 new products were launched, and the company maintains 1,826+ product items serving over 100 million people across 40+ countries.

Product and service6 records
1Branded Generic Medicines (Rx)
CategoryPrescription Pharmaceuticals
Description

Prescription branded generic medicines covering cardiology, oncology, respiratory, CNS, and diabetes therapeutic areas, positioned as cost-effective alternatives to originator products for healthcare providers, pharmacies, and public procurement organizations across Europe.

2OTC and Consumer Healthcare Products
CategoryConsumer Healthcare
Description

Over-the-counter medications, natural-based products, and nutritional supplements sold through pharmacies and retail channels across European markets, including brands acquired from Aboca in 2025.

3Biosimilar Medicines
CategoryBiosimilars
Description

Biosimilar products co-developed with mAbxience and licensed from Lupin, commercialized across European markets to expand access to biologic therapies.

4Zent2U B2B Platform
CategoryB2B Pharmaceutical Services
Description

Specialized B2B platform offering API (Active Pharmaceutical Ingredient) supply, CDMO (Contract Development and Manufacturing Organization) services, and outlicensing of proprietary know-how to pharmaceutical partners, with deep expertise in cardiology, urology, oncology, neurology, and hormonal therapies.

5Prague Scientific
CategoryRegulatory and Pharmacovigilance Services
Description

Comprehensive development and scientific services supporting every phase of the drug lifecycle from concept to market compliance, including API and formulation R&D, manufacturing, pharmacovigilance, and regulatory affairs.

6API Supply and CDMO Manufacturing Services
CategoryContract Manufacturing Services
Description

Active Pharmaceutical Ingredient (API) supply and contract development and manufacturing services provided to pharmaceutical companies through Zentiva's four owned plants and external manufacturing network.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Zentiva and Lupin signed a licensing and supply agreement for a biosimilar TNF-alpha inhibitor drug in 2025, expanding biosimilar portfolio offerings.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Zentiva acquired original brands from Aboca in 2025 to expand the OTC portfolio of natural-based products across Europe.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Zentiva and Adalvo signed a licensing agreement for therapeutic areas of respiratory medicine, CNS, and dermatology across Europe in 2023, strengthening Zentiva's portfolio in these key therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Launch of first biosimilar medicine in collaboration with mAbxience across 21 countries in Europe in 2021, representing a significant strategic partnership for biosimilar development and commercialization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership through Prague Scientific with PARC (Pharmaceutical Applied Research Centre) for applied pharmaceutical research, combining scientific excellence with creativity and bold thinking to deliver high-quality, affordable medicines.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Zentiva collaborates with BusinessEurope as a member of the advisory and support group, engaging in dialogues to shape competitive and sustainable EU industrial policy with a focus on safe medicine manufacturing and supply chains.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Zentiva is a proud member of Medicines for Europe, which represents pharmaceutical companies supplying the largest share of medicines in Europe. Actively contributes as a member of the executive team, board, and several committees. Adheres to the Code of Conduct ensuring ethical marketing practices.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Zentiva is a member of Genas, the Slovak Association for Generic and Biosimilar Medicines, which unites 13 pharmaceutical companies and advocates for accessible and sustainable treatment for patients and healthcare system sustainability.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Slovenian generic pharma manufacturer with strong CEE, Eastern European, and Western European presence and similar therapeutic focus in cardiovascular, CNS, and oncology—directly comparable to Zentiva's CEE origins and branded generic strategy.

TypeRegional player
Description

Polish-based generic pharma manufacturer with strong CEE presence and API manufacturing capabilities—comparable to Zentiva's CEE focus and API/CDMO offering but more regionally concentrated.

TypeBroad incumbent
Description

MENA-rooted global pharma with strong European generics business; comparable in broad generic portfolio and injectables focus, although the geographic mix differs from Zentiva's European-centric footprint.

TypeDirect peer
Description

PE-owned European generic pharma and consumer healthcare company with similar product portfolio across cardiology, oncology, and CNS, plus extensive Eastern European footprint—closely comparable to Zentiva's franchise model and CEE-heavy presence.

TypeEmerging player
Description

Iceland-based pure-play biosimilar developer with pan-European commercialization partnerships—comparable to Zentiva's biosimilar ambitions via mAbxience and Lupin partnerships.

TypeBroad incumbent
Description

Indian-headquartered global generic pharma with pan-European distribution and API manufacturing—comparable to Zentiva's European generic channel and Ankleshwar/API capabilities, although more diversified across therapeutic areas.

TypeDirect peer
Description

Global generics and specialty pharma formed from Mylan and Upjohn, with broad generic and biosimilar portfolio across Europe and emerging markets—directly comparable across therapeutic areas and contract manufacturing services.

TypeDirect peer
Description

World's largest generic pharmaceutical manufacturer with extensive European presence across branded generics, specialty, and biosimilars—directly comparable to Zentiva's portfolio breadth, therapeutic area focus, and large-scale manufacturing footprint.

9Sandoz
TypeDirect peer
Description

Novartis's generics and biosimilars spinoff, a leading European generic pharma with broad small-molecule portfolio, biosimilar pipeline, and pan-European distribution—directly comparable to Zentiva's branded generics and Zent2U CDMO model.

TypeEmerging player
Description

Indian-headquartered global generic pharma with a growing biosimilar franchise—comparable to Zentiva (and a Zentiva licensing partner via the Lupin TNF-alpha biosimilar) across generic APIs and biosimilars.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance15 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zentiva

Generic Pharmaceuticalszentiva.sk

Zentiva is a European pharmaceutical company developing, manufacturing, and supplying generic, branded generic, OTC, and biosimilar medicines, serving 100+ million patients across 40+ countries through 31 branches and 1,800+ medical representatives.

What Zentiva does

Zentiva is a European pharmaceutical company that develops, manufactures, and distributes high-quality, affordable generic and branded generic medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars. Its portfolio spans 1,826+ product items covering cardiology, oncology, respiratory, central nervous system, and diabetes therapeutic areas, serving more than 100 million people across 40+ countries in Europe and beyond. The company operates four owned manufacturing plants in Czech Republic, Romania (two sites), and India, producing 718 million Standard Manufacturing Units annually, supplemented by a network of external manufacturing partners. Its R&D footprint comprises two centers with 250+ experts registered 509 new product filings in 2025, supported by an Open Innovation Program and the PARC academic partnership through Prague Scientific.

Zentiva generates revenue across four primary streams: prescription generic and branded generic medicines sold through 31 active branches and 6 representations by 1,800+ medical representatives; OTC and consumer healthcare products distributed through pharmacies and retail; the Zent2U B2B platform offering API supply, CDMO services, and know-how licensing; and Prague Scientific pharmacovigilance and regulatory services. The company positions itself as a cost-effective alternative to originator brands, supporting healthcare system sustainability across European markets. Pricing is regulated by national healthcare authorities, with quote-based and contract-based terms for institutional customers and public procurement organizations.

Founded in 1993 after the Velvet Revolution, with pharmaceutical roots tracing to 1488 in Prague, Zentiva was publicly listed (2004), merged with Sanofi (2008), spun off to Advent International (2018), and most recently acquired by GTCR in April 2026. Under current ownership, the company employs 5,400+ professionals across 30+ countries and has expanded aggressively through acquisitions (Creo Pharmaceuticals, Solacium, Alvogen CEE, Helvepharm, Ankleshwar plant, Aboca OTC brands) and licensing partnerships (mAbxience biosimilars, Adalvo, Lupin). Recent strategic moves include the Lupin biosimilar deal and Aboca OTC acquisition in 2025, with a stated goal to reach 1 in 5 people in Europe by 2028.

Zentiva firmographics

Firmographics
Name
Zentiva
Legal name
Zentiva Group, a.s.
Website
https://zentiva.sk
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
Zentiva is a European pharmaceutical company developing, manufacturing, and supplying generic, branded generic, OTC, and biosimilar medicines, serving 100+ million patients across 40+ countries through 31 branches and 1,800+ medical representatives.
Ownership category
akta.pro rank

Zentiva industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Generic pharmaceuticals
  • Branded generic medicines
  • OTC consumer healthcare
  • API manufacturing services
  • Biosimilar medicines

Where Zentiva is headquartered

Location

Headquarters

HQ city
Bratislava

Offices31 records

Markets served

Zentiva business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Generic and Branded Generic Medicines (Rx): Prescription generic and branded generic medicines covering therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. Products include original brands protected by patents or data exclusivity, and branded generics serving as equivalent alternatives to originator products. Revenue generated through direct sales to healthcare providers, pharmacies, and public procurement across Europe.
  2. OTC and Consumer Healthcare Products: Over-the-counter products and nutritional supplements sold through pharmacies and retail channels, including natural-based OTC products acquired from Aboca in 2025. Revenue from consumer-facing OTC sales across European markets.
  3. B2B Platform Services (Zent2U): Specialized B2B platform offering API (active pharmaceutical ingredient) supply, CDMO (contract development and manufacturing) services, and licensing of know-how to partners, with deep expertise in cardiology, urology, oncology, neurology, and hormonal therapies.
  4. Scientific and Regulatory Services (Prague Scientific): High-quality pharmacovigilance and regulatory services for prescription drugs (Rx), OTC, and non-drug products through Prague Scientific, supporting every phase of the drug lifecycle from concept to product compliance maintenance.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractPrescription generic and branded medicines — regulated pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Zentiva product offering

Product offering

Core offering

Zentiva develops, manufactures, and supplies high-quality, affordable generic and branded generic prescription medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars across therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. The company maintains a portfolio of 1,826+ product items, produced at four owned manufacturing plants in the Czech Republic, Romania, and India, and distributed across 40+ countries to over 100 million people via 31 commercial branches and 1,800+ medical representatives. It also operates the Zent2U B2B platform for API supply, CDMO services, and licensing, and Prague Scientific for pharmacovigilance and regulatory services.

Product overview

Zentiva is a European pharmaceutical company developing, manufacturing, and supplying high-quality, affordable medicines. Its portfolio consists of prescription (Rx) medicines and over-the-counter (OTC) consumer healthcare products across therapeutic areas including cardiology, oncology, respiratory care, CNS, and diabetes. The offering is structured around branded generic medicines and specialized products, supported by two core B2B service platforms: Zent2U (providing API supply, CDMO services, and outlicensing) and Prague Scientific (providing R&D, manufacturing, pharmacovigilance, and regulatory affairs services). The company also operates an Open Innovation Program and research partnerships including PARC. In 2024, more than 140 new products were launched, and the company maintains 1,826+ product items serving over 100 million people across 40+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Zent2U: Specialized B2B platform offering API, CDMO services, and licensing of know-how to partners in key therapeutic areas including cardiology, urology, oncology, neurology, and hormonal treatments
  • Prague Scientific

Products and services

  • Branded Generic Medicines (Rx) Prescription branded generic medicines covering cardiology, oncology, respiratory, CNS, and diabetes therapeutic areas, positioned as cost-effective alternatives to originator products for healthcare providers, pharmacies, and public procurement organizations across Europe.
  • OTC and Consumer Healthcare Products Over-the-counter medications, natural-based products, and nutritional supplements sold through pharmacies and retail channels across European markets, including brands acquired from Aboca in 2025.
  • Biosimilar Medicines Biosimilar products co-developed with mAbxience and licensed from Lupin, commercialized across European markets to expand access to biologic therapies.
  • Zent2U B2B Platform Specialized B2B platform offering API (Active Pharmaceutical Ingredient) supply, CDMO (Contract Development and Manufacturing Organization) services, and outlicensing of proprietary know-how to pharmaceutical partners, with deep expertise in cardiology, urology, oncology, neurology, and hormonal therapies.
  • Prague Scientific Comprehensive development and scientific services supporting every phase of the drug lifecycle from concept to market compliance, including API and formulation R&D, manufacturing, pharmacovigilance, and regulatory affairs.
  • API Supply and CDMO Manufacturing Services Active Pharmaceutical Ingredient (API) supply and contract development and manufacturing services provided to pharmaceutical companies through Zentiva's four owned plants and external manufacturing network.

Quantifiable outcome

  • 100+ million people served across 40+ countries in Europe and beyond
  • +4 more outcomes

Companies that use Zentiva

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Zentiva technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Zentiva partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • LupincoreStrategic or Co-development Partner · 1 January 2025Zentiva and Lupin signed a licensing and supply agreement for a biosimilar TNF-alpha inhibitor drug in 2025, expanding biosimilar portfolio offerings.
  • AbocaminorStrategic or Co-development Partner · 1 January 2025Zentiva acquired original brands from Aboca in 2025 to expand the OTC portfolio of natural-based products across Europe.
  • AdalvocoreStrategic or Co-development Partner · 1 January 2023Zentiva and Adalvo signed a licensing agreement for therapeutic areas of respiratory medicine, CNS, and dermatology across Europe in 2023, strengthening Zentiva's portfolio in these key therapeutic areas.
  • mAbxiencecoreStrategic or Co-development Partner · 1 January 2021Launch of first biosimilar medicine in collaboration with mAbxience across 21 countries in Europe in 2021, representing a significant strategic partnership for biosimilar development and commercialization.
  • PARC (Pharmaceutical Applied Research Centre)coreStrategic or Co-development PartnerAcademic partnership through Prague Scientific with PARC (Pharmaceutical Applied Research Centre) for applied pharmaceutical research, combining scientific excellence with creativity and bold thinking to deliver high-quality, affordable medicines.
  • BusinessEuropeminorStrategic or Co-development PartnerZentiva collaborates with BusinessEurope as a member of the advisory and support group, engaging in dialogues to shape competitive and sustainable EU industrial policy with a focus on safe medicine manufacturing and supply chains.
  • Medicines for EuropecoreStrategic or Co-development PartnerZentiva is a proud member of Medicines for Europe, which represents pharmaceutical companies supplying the largest share of medicines in Europe. Actively contributes as a member of the executive team, board, and several committees. Adheres to the Code of Conduct ensuring ethical marketing practices.
  • Genas (Generické a biosimilárne lieky)minorStrategic or Co-development PartnerZentiva is a member of Genas, the Slovak Association for Generic and Biosimilar Medicines, which unites 13 pharmaceutical companies and advocates for accessible and sustainable treatment for patients and healthcare system sustainability.

Scale indicators15 records

Recent moves13 records

Expansion highlights7 records

Zentiva competitors and assessment

Company assessment

Direct peers

  • Krka: Slovenian generic pharma manufacturer with strong CEE, Eastern European, and Western European presence and similar therapeutic focus in cardiovascular, CNS, and oncology—directly comparable to Zentiva's CEE origins and branded generic strategy.
  • Stada Arzneimittel: PE-owned European generic pharma and consumer healthcare company with similar product portfolio across cardiology, oncology, and CNS, plus extensive Eastern European footprint—closely comparable to Zentiva's franchise model and CEE-heavy presence.
  • Viatris: Global generics and specialty pharma formed from Mylan and Upjohn, with broad generic and biosimilar portfolio across Europe and emerging markets—directly comparable across therapeutic areas and contract manufacturing services.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive European presence across branded generics, specialty, and biosimilars—directly comparable to Zentiva's portfolio breadth, therapeutic area focus, and large-scale manufacturing footprint.
  • Sandoz: Novartis's generics and biosimilars spinoff, a leading European generic pharma with broad small-molecule portfolio, biosimilar pipeline, and pan-European distribution—directly comparable to Zentiva's branded generics and Zent2U CDMO model.

Regional players

  • Polpharma: Polish-based generic pharma manufacturer with strong CEE presence and API manufacturing capabilities—comparable to Zentiva's CEE focus and API/CDMO offering but more regionally concentrated.

Broad incumbents

  • Hikma Pharmaceuticals: MENA-rooted global pharma with strong European generics business; comparable in broad generic portfolio and injectables focus, although the geographic mix differs from Zentiva's European-centric footprint.
  • Aurobindo Pharma: Indian-headquartered global generic pharma with pan-European distribution and API manufacturing—comparable to Zentiva's European generic channel and Ankleshwar/API capabilities, although more diversified across therapeutic areas.

Emerging players

  • Alvotech: Iceland-based pure-play biosimilar developer with pan-European commercialization partnerships—comparable to Zentiva's biosimilar ambitions via mAbxience and Lupin partnerships.
  • Lupin: Indian-headquartered global generic pharma with a growing biosimilar franchise—comparable to Zentiva (and a Zentiva licensing partner via the Lupin TNF-alpha biosimilar) across generic APIs and biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Zentiva social profiles

Digital presence

Zentiva compliance and trust

Trust signal

Compliance15 records

Zentiva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zentiva leadership team

Management profile

Number of profiles

Profiles10 records

Zentiva subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Zentiva funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zentiva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zentiva

What does Zentiva do?

Zentiva develops, manufactures, and supplies high-quality, affordable generic and branded generic prescription medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars across therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. The company maintains a portfolio of 1,826+ product items, produced at four owned manufacturing plants in the Czech Republic, Romania, and India, and distributed across 40+ countries to over 100 million people via 31 commercial branches and 1,800+ medical representatives. It also operates the Zent2U B2B platform for API supply, CDMO services, and licensing, and Prague Scientific for pharmacovigilance and regulatory services.

Is Zentiva a public or private company?

Zentiva is a private company. It is classified as private equity controlled and is currently operating.

When was Zentiva founded?

Zentiva was founded in 1993. It employs 11 to 50 people.

Where is Zentiva based?

Zentiva is headquartered in Bratislava.

How does Zentiva make money?

Four revenue lines are on record. Generic and Branded Generic Medicines (Rx) is the primary driver. The others are OTC and Consumer Healthcare Products, B2B Platform Services (Zent2U) and scientific and Regulatory Services (Prague Scientific).

Who are Zentiva's main competitors?

Direct peers on record are Krka, Stada Arzneimittel, Viatris, Teva Pharmaceutical Industries and Sandoz. Polpharma is listed as a regional player. Broad incumbents are Hikma Pharmaceuticals and Aurobindo Pharma. Emerging players are Alvotech and Lupin.

Does Zentiva have an API?

No public API is recorded for Zentiva.

What industry is Zentiva in?

Zentiva's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals